Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015

Tango Therapeutics and Erasca opened enrollment in a Phase 1/2 study of oral PRMT5 inhibitor vopimetostat combined with pan-RAS molecular glue ERAS-0015. The trial will enroll patients with MTAP-deleted pancreatic ductal adenocarcinoma and MTAP-deleted/RAS-mutant non-small cell lung cancer; Tango's Malte Peters said clinical activity, durability and tolerability observed to date support the combination's potential.

Analysis

The market-relevant signal is validation of a combination hypothesis, not a near-term commercial inflection. Opening enrollment creates a long path to decision-grade evidence; the quoted characterization of prior activity is not enough to assess response rate, durability, safety, or whether benefit is attributable to the combination. With no trial-level results or collaboration economics supplied, do not translate the announcement into a quantified value uplift for either company.

If the approach works, it could make MTAP-deleted status a way to extend RAS-directed treatment into tumors where single-agent RAS inhibition is inadequate, benefiting both programs and increasing competitive pressure on other RAS and PRMT5 approaches. Conversely, overlapping toxicity, dose reductions, or difficult patient selection could undermine the combination and limit addressable enrollment. Competition for biomarker-defined patients may also slow recruitment across studies.

Days: sentiment may support both stocks, but the announcement alone is weak evidence for a durable rerating. Over 1–3 months, watch for enrollment pace, trial design details, and any independently assessable clinical update. Over 6–18 months, safety and efficacy in each tumor cohort matter far more than enrollment status. The contrarian point: investors may overvalue a new trial opening while underweighting the time, attrition, and tolerability risk between enrollment and usable data.

Key Decisions for Investors

• No immediate directional trade on this announcement alone; avoid chasing ERAS or TNGX on company-described activity without cohort-level response, duration, and safety data.
• Keep ERAS and TNGX on a clinical-catalyst watchlist. Verify trial enrollment pace, dose levels, cohort-specific outcomes, discontinuations, and the economic terms governing each company's participation before revising asset value.
• Treat tolerability and efficacy as thesis-falsification tests: dose-limiting toxicity or frequent dose interruptions, weak activity in either cohort, or materially slower-than-expected recruitment would weaken the combination thesis.
• Reassess only when the companies provide interpretable clinical data; a positive signal should be durable and cohort-specific, not merely a pooled response claim. Until then, prefer no position over a speculative pair trade.